J 2022

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

INFANTE, Maria Stefania, Jon SALMANTON-GARCIA, Ana FERNANDEZ-CRUZ, Francesco MARCHESI, Ozren JAKSIC et. al.

Základní údaje

Originální název

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Autoři

INFANTE, Maria Stefania, Jon SALMANTON-GARCIA (garant), Ana FERNANDEZ-CRUZ, Francesco MARCHESI, Ozren JAKSIC, Barbora WEINBERGEROVÁ (203 Česká republika, domácí), Caroline BESSON, Rafael F DUARTE, Federico ITRI, Toni VALKOVIC, Tomas SZOTKOVSKI, Alessandro BUSCA, Anna GUIDETTI, Andreas GLENTHOJ, Graham P COLLINS, Valentina BONUOMO, Uluhan SILI, Guldane Cengiz SEVAL, Marina MACHADO, Raul CORDOBA, Ola BLENNOW, Ghaith ABU-ZEINAH, Sylvain LAMURE, Austin KULASEKARARAJ, Iker FALCES-ROMERO, Chiara CATTANEO, Van Doesum JAAP, Klara PIUKOVICS, Ali S OMRANI, Gabriele MAGLIANO, Marie-Pierre LEDOUX, de Ramon CRISTINA, Alba CABIRTA, Luisa VERGA, Alberto LOPEZ-GARCIA, Da Silva Maria GOMES, Zlate STOJANOSKI, Stef MEERS, Tobias LAHMER, Sonia MARTIN-PEREZ, Julio DAVILA-VALS, Van Praet JENS, Michail SAMARKOS, Yavuz M BILGIN, Linda Katharina KARLSSON, Josip BATINIC, Anna NORDLANDER, Martin SCHONLEIN, Martin HOENIGL, Zdenek RACIL, Milos MLADENOVIC, Michaela HANAKOVA, Giovanni Paolo Maria ZAMBROTTA, De Jonge NICK, Tatjana ADZIC-VUKICEVIC, Raquel NUNES-RODRIGUES, Lucia PREZIOSO, Milan NAVRATIL, Monia MARCHETTI, Annarosa CUCCARO, Maria CALBACHO, Antonio GIORDANO, Oliver A CORNELY, Jose-Angel HERNANDEZ-RIVAS a Livio PAGANO

Vydání

Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2022, 2234-943X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.700

Kód RIV

RIV/00216224:14110/22:00128430

Organizační jednotka

Lékařská fakulta

UT WoS

000879004600001

Klíčová slova anglicky

SARS-CoV-2; targeted drugs; infection risk; immune system COVID19; lymphoproliferative diseases (LPD); chronic lymphocytic leukemia (CLL); non-Hodgkin lymphoma (NHL)

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 31. 1. 2023 10:45, Mgr. Tereza Miškechová

Anotace

V originále

Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.